The day in conversation for 2026-10-20

The discussion: Ines: The part about requiring agreement between the topology agent and the functional evidence agent really stands out to me; it moves beyond just merging datasets and into genuine consensus building for a candidate. Marcus: Exactly, I think that's where the real statistical muscle is. It’s not enough for either system to be good on its own—that’s what we've been struggling with when we tried those single-source approaches last week; they just gave us noise. Yuki: And it seems the benefit isn't just that it’s more reliable in terms of odds ratios, but that it changes the prediction landscape. The fact that they can predict driver status in some contexts but not others, while permutation testing backs this up, suggests we are hitting a fundamental limitation of relying on single-agent predictive power. Ines: Right, and I wonder how much weight we should give to those context differences. If it’s only strong in certain cancer types or focal genes—where do we draw the line before we assume this method is universally superior? Marcus: It brings us back to that earlier point about generalization. We need to be careful not to over-hype the power just because it worked on a specific subset of focal genes. The core issue isn't just getting agreement; it’s whether that added confidence actually translates into anything actionable outside of those controlled environments we tested previously. Yuki: That’s the clincher, isn't it? If we can achieve high statistical power in finding a candidate, but that candidate doesn't represent a clinically meaningful discovery in the real world, then the entire computational elegance of the orchestration method is just an elegant